<DOC>
	<DOCNO>NCT00651079</DOCNO>
	<brief_summary>To determine safety , tolerability Pharmacokinetics GSK1247303</brief_summary>
	<brief_title>GSK1247303 First Time Human Study</brief_title>
	<detailed_description />
	<criteria>The subject healthy . Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test 12lead ECG . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 50 year age . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) : A male eligible enter participate study surgically sterile OR either agree abstain sexual intercourse female partner agree use condom/spermicide , addition female partner use another form contraception outline Section 8.1 . Body weight &gt; =50 kg ( 110 lb . ) men &gt; = 45 kg ( 99 lb ) woman body mass index ( BMI ) within range 18.531.0 kg/m2 ( inclusive ) . A signed date write informed consent obtain subject subject 's legal representative prior screen . Subject must capable give write informed consent , include compliance requirement restriction list consent form . As result medical interview , physical examination , screen investigation , Investigator considers subject unfit study . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass graft surgery percutaneous transluminal coronary angioplasty clinically significant cardiac disease . History/evidence clinically significant pulmonary disease . Has positive prestudy Hepatitis B surface antigen ; positive hepatitis C ( HCV ) antibody detectable HCV ribonucleic acid ( RNA ) ; positive HIV1 antibody result . Has history regular alcohol consumption average &gt; 7 drinks/week woman &gt; 14 drinks/week men within 6 month screen visit . Note : 1 drink equivalent 12 g alcohol = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . Unwilling abstain alcohol 48 hour prior start dose collection final pharmacokinetic sample treatment period . Has history regular use tobacco nicotinecontaining product within 3 month screen visit . The subject positive prestudy drug and/or alcohol screen . Unwilling refrain use illicit drug adhere protocolstated restriction participate study . The subject receive investigational drug participate research trial within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Participation study would result donation blood excess 500 mL within 56 day period . Note : This include plasma donation . History presence allergy intolerance study drug component drug class , history drug allergy , opinion physician responsible , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Note : `` Study '' `` investigational '' drug include GSK1247303 placebo . Use prescription nonprescription drug , include antacid , vitamin , herbal dietary supplement ( include St John 's Wort iron supplement ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin value great upper limit normal . A single repeat allow eligibility determination . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . History significant renal hepatic disease . History Gilbert 's syndrome . Exclusion Criteria 24Hour Screening Holter per protocol . Exclusion criterion screen ECG per protocol ( single repeat allow eligibility determination ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>GSK1247303 ,</keyword>
	<keyword>Integrase ,</keyword>
	<keyword>First Time Human</keyword>
</DOC>